Riskpilot← Back to searchSign inGet full accessORIFARM GENERICS A/S
A/SActiveCVR 25674030Energivej 15Wholesale of pharmaceutical and medical goods · NACE 4646Est. 2000258 employees
Revenue 2024
DKK 2,3B
+10% vs 2023
EBITDA margin
4.7%
+1% vs 2023
Equity ratio
53.3%
Financial strength
Net profit 2024
DKK 59,9M
-5% vs 2023
| Revenue | DKK 2,3B | +10% |
| EBITDA | DKK 109,4M | +1% |
| Net profit | DKK 59,9M | -5% |
| Total assets | DKK 1B | -25% |
| Equity | DKK 554,5M | +12% |
| Employees | 258 | — |
Legal name
ORIFARM GENERICS A/S
CVR number
25674030
Legal form
Aktieselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
15. oktober 2000
Share capital
DKK 1.000.000
Employees
258 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den administrerende direktør og et bestyrelsesmedlem i forening, eller af to bestyrelsesmedlemmer i forening.
Company purpose
Selskabets formål er at foretage salg af fortrinsvis generiske lægemidler i Danmark.
Address
Energivej 15
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 30.716 | 32.083 | 40.010 | 169.885 | 171.953 | 504.442 | 545.016 | 688.426 | 1.757.348 | 2.074.832 | 2.137.930 | 2.343.003 |
| Staff expenses | -27.313 | -28.385 | -35.905 | -54.577 | -59.063 | -61.868 | -54.407 | -74.300 | -138.954 | -181.415 | -229.007 | -242.890 |
| EBITDA | 3.403 | 3.699 | 4.105 | 115.308 | 112.890 | 100.825 | 142.639 | 199.878 | 190.375 | 80.073 | 108.671 | 109.414 |
| Depreciation & amort. | -1.736 | -2.618 | -3.135 | -7.678 | -11.101 | -8.241 | -8.411 | -14.267 | -9.727 | -10.520 | -13.041 | -10.358 |
| EBIT | 1.667 | 1.081 | 970 | 107.630 | 101.789 | 92.584 | 134.228 | 185.611 | 180.648 | 69.553 | 95.630 | 99.056 |
| Net financials | -138 | -315 | -2 | -670 | -2.938 | -2.632 | -891 | 1.076 | 10.101 | -19 | -15.369 | -22.014 |
| Profit before tax | 1.529 | 766 | 968 | 106.960 | 98.851 | 89.952 | 133.337 | 186.687 | 190.749 | 69.534 | 80.261 | 77.042 |
| Tax | 205 | 216 | 363 | 23.710 | 22.500 | 19.897 | 29.482 | 41.173 | 40.609 | 15.072 | 17.333 | 17.182 |
| Net profit | 1.324 | 550 | 605 | 83.250 | 76.351 | 70.055 | 103.855 | 145.514 | 150.140 | 54.462 | 62.928 | 59.860 |
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 34.275 | 31.290 | 46.455 | 240.607 | 259.688 | 295.017 | 330.196 | 455.784 | 1.172.126 | 1.345.179 | 1.382.406 | 1.040.284 |
| Equity | 6.882 | 7.432 | 8.038 | 60.420 | 86.770 | 116.825 | 145.680 | 201.194 | 527.257 | 431.719 | 494.647 | 554.507 |
| Long-term debt | 0 | 0 | 0 | -6.728 | -6.854 | -8.953 | 2.180 | 7.349 | 0 | 0 | 0 | 0 |
| Short-term debt | 24.426 | 21.403 | 37.256 | 173.459 | 166.064 | 169.239 | 171.867 | 236.868 | 634.665 | 903.030 | 876.907 | 473.102 |
| Total debt | 24.426 | 21.403 | 37.256 | 173.459 | 166.064 | 169.239 | 174.047 | 244.217 | 634.665 | 903.030 | 876.907 | 473.102 |
EBITDA margin
4.7%
This company
15.8%
Market median
-70% vs market
20132024
Equity ratio
53.3%
This company
38.2%
Market median
+40% vs market
20132024
Return on equity
10.8%
This company
18.4%
Market median
+41% vs market
20132024
Net profit margin
2.6%
This company
8.1%
Market median
-68% vs market
20132024
Asset turnover
2.25×
This company
1.12×
Market median
+101% vs market
20132024
Debt / equity
0.88×
This company
0.62×
Market median
+42% vs market
20132024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TB Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
KH Chief Executive Officer | Chief Executive Officer | 2018 | — | — |
UE Chief Executive Officer | Chief Executive Officer | 2013 | — | — |
JK Chief Executive Officer | Chief Executive Officer | 2009 | — | — |
ES Chief Executive Officer | Chief Executive Officer | 2012 | — | — |
PA Management | Management | 2000 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2000 | — | — | |
| Board of Directors | 2003 | — | — | |
| Chairman | 2011 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2008 | — | — | |
| Board of Directors | 2011 | — | — | |
| Chairman | 2000 | — | — | |
| Board of Directors | 2012 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2001 | — | — | |
| Board of Directors | 2003 | — | — | |
| Chairman | 2001 | — | — | |
| Board of Directors | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
ORIFARM GENERICS HOLDING A/S | Company | 100.0% | 100.0% | 2004 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Orifarm Holding A/S
ORIFARM GENERICS A/S Board members of ORIFARM GENERICS A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Thomas Brandhof | Chief Executive Officer | 0 companies |
| Karsten Haumann | Chief Executive Officer | 0 companies |
| Ulrik Ernst Rasmussen | Chief Executive Officer | 0 companies |
| Jan Kruse Hansen | Chief Executive Officer | 0 companies |
| Erik Sandberg | Chief Executive Officer | 0 companies |
| Peter Andreas Stakemann | Management | 0 companies |
| Annemette Heller | Board of Directors | 0 companies |
| Per Munk Laustsen | Board of Directors | 0 companies |
| Hans Carl Bøgh-Sørensen | Chairman | 0 companies |
| Mads Fink Eriksen | Board of Directors | 0 companies |
| Ole Ibsen | Board of Directors | 0 companies |
| Birgitte Bøgh-Sørensen | Board of Directors | 0 companies |
| Kim Madsen | Chairman | 0 companies |
| Hans Christian Eberhard Groth Teisen | Board of Directors | 0 companies |
| Dennis Dencher | Board of Directors | 0 companies |
| Niels Thorborg | Board of Directors | 0 companies |
| Ulrik Kronborg Markussen | Board of Directors | 0 companies |
| Ole Michael Friis | Chairman | 0 companies |
| Nicki Lund Kristensen | Board of Directors | 0 companies |